Description of Invention:
Due to the increase in drug resistance among bacteria, continued progress in the development of new antibiotic treatments is needed. Available for licensing and commercial development is the small protein SrgT, its analogs and related peptides. SrgT is a 43 amino acid protein that effectively inhibits bacterial growth. This protein likely exerts its antibiotic action by inhibiting the metabolism of glucose in these microorganisms. The claimed invention includes methods for SrgT synthesis and suggested modifications for production of SrgT analogs and related peptides, which may remain effective against potential SrgT resistant bacteria. Thus, the current technology provides a novel approach to the treatment and prevention of bacterial infections.
Application:
Novel therapeutics and prophylactics for bacterial infections
Development Status:
Preclinical data is available at this time
Inventors:
Carin K. Vanderpool and Susan Gottesman (NCI)
Patent Status:
DHHS Reference No. E-166-2006/0 --
U.S. Provisional Application No. 60/799,830 filed 11 May 2006
Relevant Publication: CK Vanderpool, S Gottesman. Involvement of a novel transcriptional activator and small RNA in post-transcriptional regulation of the glucose phosphoenolpyruvate phosphotransferase system. Mol Microbiol. 2004 Nov; 54(4):1076-1089. [PubMed abs]
Licensing Status: Available for non-exclusive and exclusive licensing.
For Additional Information Please Contact: Cristina Thalhammer-Reyero PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4507
Email: thalhamc@mail.nih.gov
Fax: (301) 402-0220